Exelixis and Bristol-Myers Squibb (BMS) have announced a clinical development collaboration for a programme, co-funded by each company, to evaluate a combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) as a first-line treatment for advanced renal cell carcinoma, either with or without ipilimumab (Yervoy). The development programme will include a phase 3 pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma, a form of liver cancer, and potentially other tumour types.
Details for the phase 3 clinical trial in renal cell carcinoma are yet to be released.
